ClinicalTrials.gg
CompletedNCT04714359MAPPUSXUpdated Jun 6, 2025Results posted

A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

A Phase 3 interventional study of Midomafetamine HCl in PTSD, sponsored by Lykos Therapeutics. Completed at 15 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
87
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic — 11 open to participants now, 12 under way, 1 of them phase 3. N-Methyl-3,4-methylenedioxyamphetamine · Stress Disorders, Post-Traumatic.

Enrollment
6th of 38
87 · median 25
Started
2021
with 3 others
Phase 3
6 of 38
none open now
Registered
18th of 38
by date
Lead sponsor
16 of 38
Lykos Therapeutics

Among the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, this one is the 6th largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, and was the 18th registered.

Stress Disorders, Post-Traumatic

2,688 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 606 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

11 of the 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About N-Methyl-3,4-methylenedioxyamphetamine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies testing N-Methyl-3,4-methylenedioxyamphetamine in Stress Disorders, Post-Traumatic, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing PTSD symptoms in people with PTSD who received placebo in a prior MDMA-assisted therapy study.

The main question it aims to answer is:

Do PTSD symptoms decrease in people who receive a flexible dose of MDMA (120 or 180 mg MDMA HCl) with therapy in three sessions?

Participants will undergo three preparatory therapy sessions without any study drug, then three MDMA-assisted therapy sessions with a flexible dose of 80 or 120 mg, followed by three integrative therapy sessions without study drug after each MDMA-assisted therapy session.

Read the detailed description

This multi-site, open-label safety extension study assesses the efficacy and safety of MDMA-assisted psychotherapy versus psychotherapy in participants diagnosed with PTSD. The study will be conducted in N ≈ 100 participants. Participants who were randomized to the placebo arm in either of the two parent Phase 3 trials of MDMA-assisted psychotherapy and who meet all other entry criteria will be eligible and invited to participate in this study. In addition, participants in the parent Phase 3 trials who were unable to complete the study due to the COVID-19 pandemic or other unforeseen circumstances may participate in this study.

The treatment consists of an initial dose of midomafetamine HCl (80 or 120 mg), followed by a supplemental dose (40 or 60 mg) unless contraindicated, administered with manualized psychotherapy in three open-label Experimental Sessions each spaced approximately one month apart. During Experimental Session 1, participants will receive an initial dose of 80 mg of midomafetamine HCl, followed by a supplemental dose of 40 mg. During Experimental Sessions 2 and 3, participants will receive an initial dose of 80 or 120 mg of midomafetamine HCl, followed by a supplemental dose of 40 or 60 mg.

This Treatment Period is preceded by three Preparatory Sessions. During the Treatment Period, each Experimental Session is followed by three Integrative Sessions of non-drug psychotherapy. Experimental Sessions are followed by an overnight stay, with the exception of a subset of participants who will be invited to participate in a sub-study to assess the feasibility of Experimental Sessions without overnight stay. The primary study endpoint is the change from baseline in PCL-5 (PTSD Checklist for DSM-5) scores from Visit 3 to Visit 16.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Were previously enrolled in a parent study and (meet one of the following):

    1. At time of unblinding, their treatment assignment was to the placebo arm; or,
    2. Did not begin Experimental Sessions due to the COVID-19 global pandemic or other unforeseen circumstances;
    3. Completed fewer than three Experimental Sessions prior to Study Termination due to the COVID-19 global pandemic or other unforeseen circumstances.
  • Are considered in good standing with the study site at which they enrolled in a parent study; if, in the opinion of the investigator, therapy team, and Medical Monitor, the participant was compliant with protocol requirements, even if they were unable to complete all study visits.
  • Are at least 18 years old
  • Are fluent in speaking and reading the predominantly used or recognized language of the study site
  • Are able to swallow pills
  • Agree to have study visits recorded, including Experimental Sessions, Independent Rater assessments, and non-drug psychotherapy sessions
  • Must provide a contact (relative, spouse, close friend or other caregiver) who is willing and able to be reached by the investigators in the event of a participant becoming suicidal or unreachable.
  • Must agree to inform the investigators within 48 hours of any medical conditions and procedures
  • If of , must have a negative pregnancy test at study entry and prior to each Experimental Session, and must agree to use adequate through 10 days after the last Experimental Session.
  • Must not participate in any other interventional clinical trials during the duration of the study
  • Agree to the following lifestyle modifications: comply with requirements for fasting and refraining from certain medications prior to Experimental Sessions.
  • Must be willing to remain overnight at the study site after each Experimental Session and be driven home after, and commit to medication dosing, therapy, and study procedures.

Exclusion criteria

Exclusion Criteria:

  • Are not able to give adequate Have uncontrolled hypertension
  • Have a marked baseline prolongation of /QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds [ms] in males and >460 ms in females corrected by Fridericia formula)
  • Have a history of additional risk factors for Torsade de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome)
  • Have evidence or history of significant medical disorders, such as myocardial infarction, cerebrovascular accident, or aneurysm
  • Have symptomatic liver disease
  • Have recent history of hyponatremia or hyperthermia
  • Weigh less than 48 kilograms (kg)
  • Are pregnant or nursing, or are of and are not practicing an effective means of
  • Have an active illicit or prescription drug substance use disorder within 12 months
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    MDMA-assisted therapy

    Three open-label sessions of MDMA-assisted therapy, each scheduled approximately 1 month apart, with initial dose of midomafetamine HCl of 80 or 120 mg and optional supplemental dose half that of initial dose (40 or 60 mg) 1.5 to 2 hours later

    Drug: Midomafetamine HCl

Interventions

  • Initial doses per Experimental Session include 80 mg or 120 mg midomafetamine HCl, followed 1.5 to 2 hours later by a supplemental dose unless tolerability issues emerge. For an initial dose of 80 mg, a 40 mg supplemental dose will be used. For an initial dose of 120 mg, a 60 mg supplemental dose will be used. Total amounts of midomafetamine HCl to be administered per Experimental Session range from 80 mg to 180 mg.

    Also known as: 3,4-methylenedioxymethamphetamine, MDMA HCl, midomafetamine, MDMA

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Visit 16 in PCL-5 Total Score

    The Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5) is a 20-item self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the symptoms of PTSD per DSM-5. Participants indicate how much distress they have experienced in the last 2 weeks due to symptoms such as "Repeated, disturbing memories, thoughts, or images of a stressful experience from the past," "Trouble remembering important parts of a stressful experience from the past," and "Feeling irritable or having angry outbursts" on a five-point Likert-type scale (0=Not at all to 4=Extremely). The total severity score can range from 0 to 80 and lower scores indicate less PTSD symptoms.

    Time frame: Baseline enrollment to approximately 18 weeks later (Visit 16 occurs 24 to 32 days after Experimental Session 3)

Secondary outcomes

  1. Change From Baseline to Visit 16 in Sheehan Disability Scale (SDS) Total Score

    The SDS is a self-report assessment of functional impairment. The reporting period for the SDS refers to the past month. The items indicate degree of impairment in the domains of work/school, social life, and home life, with response options based on an eleven-point scale (0=not at all to 10=extremely), with higher scores indicating greater functional impairment.

    Time frame: Baseline enrollment to approximately 18 weeks later (Visit 16 occurs 24 to 32 days after Experimental Session 3)

07

Results

Posted Nov 29, 2024

Participant flow

Participants who were randomized to the placebo arm in the two parent Phase 3 trials and who meet all other entry criteria will be eligible and invited to participate in this open-label safety extension study.

Participant flow — Overall Study
MilestoneMDMA-assisted Therapy
Started87
Completed78
Not completed9

Outcome measures

PrimaryChange From Baseline to Visit 16 in PCL-5 Total Score

The Post Traumatic Stress Disorder Checklist for DSM-5 (PCL-5) is a 20-item self-report questionnaire in which respondents indicate the presence and severity of PTSD symptoms, derived from the symptoms of PTSD per DSM-5. Participants indicate how much distress they have experienced in the last 2 weeks due to symptoms such as "Repeated, disturbing memories, thoughts, or images of a stressful experience from the past," "Trouble remembering important parts of a stressful experience from the past," and "Feeling irritable or having angry outbursts" on a five-point Likert-type scale (0=Not at all to 4=Extremely). The total severity score can range from 0 to 80 and lower scores indicate less PTSD symptoms.

Time frame:
Baseline enrollment to approximately 18 weeks later (Visit 16 occurs 24 to 32 days after Experimental Session 3)
Reported as:
Least squares mean · score on a scale
Change From Baseline to Visit 16 in PCL-5 Total Score
score on a scaleMDMA-assisted Therapy
Change From Baseline to Visit 16 in PCL-5 Total Score-14.92 (-18.05 to -11.79)
SecondaryChange From Baseline to Visit 16 in Sheehan Disability Scale (SDS) Total Score

The SDS is a self-report assessment of functional impairment. The reporting period for the SDS refers to the past month. The items indicate degree of impairment in the domains of work/school, social life, and home life, with response options based on an eleven-point scale (0=not at all to 10=extremely), with higher scores indicating greater functional impairment.

Time frame:
Baseline enrollment to approximately 18 weeks later (Visit 16 occurs 24 to 32 days after Experimental Session 3)
Reported as:
Least squares mean · score on a scale
Change From Baseline to Visit 16 in Sheehan Disability Scale (SDS) Total Score
score on a scaleMDMA-assisted Therapy
Change From Baseline to Visit 16 in Sheehan Disability Scale (SDS) Total Score-4.10 (-5.95 to -2.25)

Adverse events

Collected over From baseline to end of follow up (approximately 18 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pre-Treatment MDMA-Assisted Therapy0/85 (0%)0/85 (0%)51/85 (60%)
On Day 0, 1, or 2 MDMA-Assisted Therapy0/85 (0%)0/85 (0%)84/85 (98.8%)
Treatment-Emergent Adverse Events MDMA-Assisted Therapy0/85 (0%)3/85 (3.5%)84/85 (98.8%)
Follow-Up MDMA-Assisted Therapy0/85 (0%)1/85 (1.2%)15/85 (17.6%)
Most frequent serious events
Most frequent serious events
EventPre-Treatment MDMA-Assisted TherapyOn Day 0, 1, or 2 MDMA-Assisted TherapyTreatment-Emergent Adverse Events MDMA-Assisted TherapyFollow-Up MDMA-Assisted Therapy
Abdominal sepsisInfections and infestations——1/850/85
Colonic abscessInfections and infestations——1/850/85
Diverticular perforationGastrointestinal disorders——1/850/85
DiverticulitisInfections and infestations——1/850/85
LymphadenopathyBlood and lymphatic system disorders——1/850/85
Procedural painInjury, poisoning and procedural complications——1/850/85
Retinal detachmentEye disorders——0/851/85
Most frequent other events
Showing 10 of 52
Most frequent other events
EventPre-Treatment MDMA-Assisted TherapyOn Day 0, 1, or 2 MDMA-Assisted TherapyTreatment-Emergent Adverse Events MDMA-Assisted TherapyFollow-Up MDMA-Assisted Therapy
Muscle tightnessMusculoskeletal and connective tissue disorders1/8550/8550/850/85
HeadacheNervous system disorders7/8543/8549/851/85
NauseaGastrointestinal disorders4/8533/8538/851/85
InsomniaPsychiatric disorders4/8525/8533/850/85
FatigueGeneral disorders1/8520/8532/852/85
Decreased appetiteMetabolism and nutrition disorders2/8532/8532/850/85
Suicidal ideationPsychiatric disorders14/8510/8532/857/85
AnxietyPsychiatric disorders6/8523/8527/850/85
Therapeutic response unexpectedGeneral disorders2/8523/8524/850/85
HyperhidrosisSkin and subcutaneous tissue disorders1/8524/8524/850/85

Baseline characteristics

Age, Continuous
Age, Continuous(years)MDMA-assisted Therapy
Mean41.7 ± 9.93
Sex: Female, Male
Sex: Female, Male(Participants)MDMA-assisted Therapy
Female65
Male20
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)MDMA-assisted Therapy
Hispanic or Latino12
Not Hispanic or Latino73
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MDMA-assisted Therapy
American Indian or Alaska Native0
Asian12
Native Hawaiian or Other Pacific Islander2
Black or African American8
White54
More than one race9
Unknown or Not Reported0
Education
Education(years)MDMA-assisted Therapy
Mean17.1 ± 2.34
Trauma History
Trauma History(Participants)MDMA-assisted Therapy
Veteran14
Served in combat area10
Multiple traumatic events65
08

Study locations

15 sites
  • New School Research
    Los Angeles, California 90004, United States
  • San Francisco Insight and Integration Center
    San Francisco, California 94114, United States
  • UCSF
    San Francisco, California 94122, United States
  • Aguazul-Blue Water Inc.
    Boulder, Colorado 80302, United States
  • Wholeness Center
    Fort Collins, Colorado 80525, United States
  • Ray Worthy Psychiatry
    New Orleans, Louisiana 70123, United States
  • Trauma Research Foundation
    Boston, Massachusetts 02446, United States
  • NYU
    New York, New York 10016, United States
  • New York Private Practice
    New York, New York 11012, United States
  • Zen Therapeutic Solutions, LLC
    Mount Pleasant, South Carolina 29464, United States
  • University of Wisconsin - Madison
    Madison, Wisconsin 53705-2222, United States
  • Numinus
    Vancouver, British Columbia V5R 5H3, Canada
  • Numinus
    Montréal, Quebec H2W 1Y9, Canada
  • Beer Yaakov Mental Health Center
    Beer Yaaqov, Israel
  • Tel Hashomer
    Tel Aviv, Israel
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We will share outcome data appearing in any published reports upon request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Data and study-related documents will be available when the database has been locked and data has been unblinded.

Access criteria: Interested persons should correspond with the central contact for the multisite study.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Nov 2023, 31 months.

Results were first posted in Nov 2024, 1 year after primary completion.

Of 34 phase 3 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2021
First posted
Jan 19, 2021
StartActual
Mar 8, 2021
Primary completionActual
Nov 1, 2023
CompletionActual
Nov 6, 2023
Results first posted
Nov 29, 2024
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04714359
Lead sponsor
Lykos Therapeutics
Responsible party
Sponsor
First posted
Jan 19, 2021
Start date
Mar 8, 2021
Primary completion
Nov 1, 2023
Completion
Nov 6, 2023
Results posted
Nov 29, 2024
Last update
Jun 6, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine

Start the discussion